Experienced in Metastatic Brain Tumor

Dr. Daniel H. Barnett

Radiation Oncology
Carle Health Care Incorporated
611 W Park St, 
Urbana, IL 
Offers Telehealth
Experienced in Metastatic Brain Tumor
Carle Health Care Incorporated
611 W Park St, 
Urbana, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Barnett is a Radiation Oncologist in Urbana, Illinois. Dr. Barnett is rated as an Experienced provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Angiosarcoma, Small Cell Lung Cancer (SCLC), Endometrial Cancer, and Lung Cancer.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Metastatic Brain Tumor.

Specialties
Radiation Oncology
Licenses
Radiology in IL
Hospital Affiliations
Carle Foundation Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

CARLE HEALTH CARE INCORPORATED
611 W Park St, Urbana, IL 61801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Enrollment Status: Completed
Publish Date: August 22, 2025
Intervention Type: Drug
Study Drug: Ramipril
Study Phase: Phase 2
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Radiation, Procedure, Other
Study Phase: Phase 3
View 7 Less Clinical Trials

4 Total Publications

Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.
Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 15, 2024
Similar Doctors
Advanced in Metastatic Brain Tumor
Dr. Mary A. Depaz
Radiation Oncology
Advanced in Metastatic Brain Tumor
Dr. Mary A. Depaz
Radiation Oncology

Cancer Care Specialists Of Central Illinois Sc

210 W Mckinley Ave, Suite 2, 
Decatur, IL 
 (42.9 miles away)
217-876-4700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mary Depaz is a Radiation Oncologist in Decatur, Illinois. Dr. Depaz is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Angiosarcoma, and Small Cell Lung Cancer (SCLC). Dr. Depaz is currently accepting new patients.

Experienced in Metastatic Brain Tumor
Dr. Kalika P. Sarma
Radiation Oncology
Experienced in Metastatic Brain Tumor
Dr. Kalika P. Sarma
Radiation Oncology

Carle Health Care Incorporated

611 W Park St, 
Urbana, IL 
 (0.1 miles away)
Experience:
46+ years
Languages Spoken:
English
See accepted insurances

Kalika Sarma is a Radiation Oncologist in Urbana, Illinois. Dr. Sarma has been practicing medicine for over 46 years and is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Acoustic Neuroma, Small Cell Lung Cancer (SCLC), Angiosarcoma, and Pleuropulmonary Blastoma.

Experienced in Metastatic Brain Tumor
Dr. Seong R. Cho
Radiation Oncology
Experienced in Metastatic Brain Tumor
Dr. Seong R. Cho
Radiation Oncology

Sarah Bush Lincoln Health Center

1000 Health Ctr Dr, 
Mattoon, IL 
 (43.6 miles away)
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Seong Cho is a Radiation Oncologist in Mattoon, Illinois. Dr. Cho is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Adenoid Cystic Carcinoma, Angiosarcoma, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Cho is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barnett's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile